Metsera announces pricing of initial public offering

New york, jan. 30, 2025 (globe newswire) -- metsera, inc. (nasdaq: mtsr) (“metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (nush) analog peptides to treat obesity, overweight and related conditions, today announced the pricing of its initial public offering of 15,277,778 shares of its common stock at a price to the public of $18.00 per share. all of the shares of common stock are being offered by metsera. the gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by metsera, are expected to be approximately $275.0 million, excluding any exercise of the underwriters' option to purchase additional shares. metsera's common stock is expected to begin trading on the nasdaq global select market under the ticker symbol “mtsr” on january 31, 2025. the offering is expected to close on february 3, 2025, subject to satisfaction of customary closing conditions. in addition, metsera has granted the underwriters a 30-day option to purchase up to an additional 2,291,666 shares of common stock at the initial public offering price less underwriting discounts and commissions.
MTSR Ratings Summary
MTSR Quant Ranking